Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 18 Issue 3, March 2019

‘Turning cold tumours hot’ inspired by the Review on p197.

Cover design: Susanne Harris. Image credit: Zoonar GmbH/Alamy Stock Photo (desert image); Jon Helgason/Alamy Stock Photo (flame image)

Volume 18 Issue 3

Subscribe

Comment

  • The development of oncology drugs traditionally begins by studying them in heavily pretreated patients, and then working ‘upstream’ to populations with earlier-stage disease. The recent FDA approval of an androgen receptor antagonist first in prostate cancer patients without demonstrable metastatic disease but at high-risk for metastasis, based on a novel metastasis-free survival end point developed by the FDA, could provide a template for a paradigm shift.

    • William N. Hait
    • Peter F. Lebowitz
    Comment

    Advertisement

Top of page ⤴

News & Analysis

  • News in Brief

  • Biobusiness Briefs

  • An Audience With

    • Hal Barron feels like he has been training his whole life to run R&D at GlaxoSmithKline, even if he didn’t know it at the time. His broad set of experiences — including an undergraduate degree in physics, a medical degree in cardiology, a professorship in epidemiology and biostatistics, as well as time spent steering R&D at Genentech and Roche and helping to build the Google-backed biotech Calico from scratch — will come in handy as he tackles the challenges of drug discovery and development at scale, he told Asher Mullard. After over a year on the job, he talks about doubling down on genetically validated targets, functional genomics, machine learning, immunology and more.

      • Asher Mullard
      An Audience With

  • From the Analyst's Couch

Top of page ⤴

Research Highlights

Top of page ⤴

Reviews

  • The rapid progress in cancer immuno therapy has highlighted the need for new delivery technologies. In this article, Langer, Mitchell and colleagues discuss how recent developments in drug delivery could enable new cancer immunotherapies and improve on existing ones, and examine the current delivery obstacles.

    • Rachel S. Riley
    • Carl H. June
    • Michael J. Mitchell
    Review Article

  • Interferons are key players in effective host immunological responses to malignant cells. This Review discusses new interferon-directed therapeutic opportunities — ranging from cyclic dinucleotides to genome methylation inhibitors, including combinations with other emerging therapeutic interventions — in cancer treatment.

    • Ernest C. Borden
    Review Article
Top of page ⤴

Search

Advanced search

Quick links